

Agenda item 2.a.i

Report to:	Board of Directors	Date: 4 February 2021
Report from:	Chair of the Performance Committee	
Principal Objective/	GOVERNANCE: To update the Board of Directors on	
Strategy and Title	discussions at the Performance Committee meeting on 17	
	December 2020	
Board Assurance	678, 841, 843, 865, 873, 874, 875, 1021, 1853, 1854, 2145,	
Framework Entries	2146, 2147, 2148, 2149, 2163, 2225, 2249	
Regulatory Requirement	Well Led/Code of Governance:	
Equality Considerations	None believed to apply	
Key Risks	To have clear and effective processes for assurance of	
	Committee risks	
For:	Information	

1. Significant issues of interest to the Board

The Committee agreed to a slimmed down agenda to allow Executives to prioritise urgent matters during the pandemic. SP provided an update on the current situation both within the Region and RPH.

PIPR

Safe' had moved from 'Green' last month to 'Amber'; reflecting an increase in falls and an increase in patients with pressure ulcers. IG provided assurance that neither metric revealed any concerning trend, but both were being closely monitored.

People Management & Culture had moved from previous 'Red' to 'Amber'; due to recruitment and vacancy rate reduction

Effective and Responsive metrics are both flagging 'Red' which was not surprising in the current operational environment. Theatre/cath lab capacity had been reduced, and there was high utilisation of the facilities which were open. Cancer referrals are being monitored closely to ensure patients are treated promptly once referred.

Covid-19 Performance Report

The impact of the current redeployment was not reflected in November reporting of activity recovery. Teams are working exceptionally hard, with especially high emergency activity levels in Cardiology. While the vacancy rate is very good across the Trust, it masks huge variability between wards. The Committee was mindful of the repercussions

for staff morale and wellbeing and received assurance that supporting staff is a major focus for the Trust.

Finance

It had been a strong month financially, driven by over-performance in private patient income, coupled with a reduction in the variable cost impact of ECMO. In addition, the monies from the sale of the old site have been received in full and used to repay part of the bridging loan; and the national 'true up' monies for M5 and M6 had also been received. Although CIP works continue in the background, the Committee acknowledged this was not the priority in the current COVID environment. That said, the Committee noted that there is a strong pipeline of ideas already generated, where schemes will have a positive impact on next year, while active engagement in CIP has become a part of everyday business for clinical teams.

- 2. Key decisions or actions taken by the Performance Committee None
- 3. Matters referred to other committees or individual Executives None
- 4. Other items of note None
- 5. Recommendation The Board to note the contents of this report